Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF PF-06252616 IN BOYS WITH DUCHENNE MUSCULAR DYSTROPHY

NCT02907619 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02907619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02907619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF PF-06252616 IN BOYS WITH DUCHENNE MUSCULAR DYSTROPHY
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
October 13, 2016
Completion date
November 22, 2018
Enrollment
59 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy